- Home
- KURA
KURA
Kura Oncology Inc.
as of 01-30-2026 3:54pm EST
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 830.1M | IPO Year: | N/A |
| Target Price: | $26.88 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.41 - $12.49 | Next Earning Date: | 02-25-2026 |
| Revenue: | $104,029,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 88.72% | Revenue Growth (next year): | 76.50% |
AI-Powered KURA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Kura Oncology Inc. (KURA)
Chief Legal Officer
Avg Cost/Share
$8.46
Shares
11,208
Total Value
$94,827.53
Owned After
234,043
SVP, Finance & Accounting
Avg Cost/Share
$8.46
Shares
7,142
Total Value
$60,426.32
Owned After
150,083
Chief Operating Officer
Avg Cost/Share
$8.46
Shares
1,813
Total Value
$15,339.25
Owned After
153,560
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$8.46
Shares
6,414
Total Value
$54,266.45
Owned After
184,847
Chief Medical Officer
Avg Cost/Share
$8.46
Shares
8,180
Total Value
$69,208.53
Owned After
268,615
Chief Scientific Officer
Avg Cost/Share
$8.46
Shares
1,311
Total Value
$11,091.98
Owned After
32,424
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$9.78
Shares
23,726
Total Value
$231,931.14
Owned After
32,424
SEC Form 4
Director
Avg Cost/Share
$10.98
Shares
10,000
Total Value
$109,764.00
Owned After
23,983
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Bair Teresa Brophy | KURA | Chief Legal Officer | Jan 27, 2026 | Sell | $8.46 | 11,208 | $94,827.53 | 234,043 | |
| DOYLE THOMAS JAMES | KURA | SVP, Finance & Accounting | Jan 27, 2026 | Sell | $8.46 | 7,142 | $60,426.32 | 150,083 | |
| FORD KATHLEEN | KURA | Chief Operating Officer | Jan 27, 2026 | Sell | $8.46 | 1,813 | $15,339.25 | 153,560 | |
| Powl Brian T. | KURA | Chief Commercial Officer | Jan 27, 2026 | Sell | $8.46 | 6,414 | $54,266.45 | 184,847 | |
| Leoni Mollie | KURA | Chief Medical Officer | Jan 27, 2026 | Sell | $8.46 | 8,180 | $69,208.53 | 268,615 | |
| Burrows Francis | KURA | Chief Scientific Officer | Jan 27, 2026 | Sell | $8.46 | 1,311 | $11,091.98 | 32,424 | |
| Burrows Francis | KURA | Chief Scientific Officer | Dec 18, 2025 | Sell | $9.78 | 23,726 | $231,931.14 | 32,424 | |
| Hasnain Faheem | KURA | Director | Dec 9, 2025 | Sell | $10.98 | 10,000 | $109,764.00 | 23,983 |
Compare KURA vs Leading Stocks
See how KURA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "KURA Kura Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.